MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Amgen Company Profile (NASDAQ:AMGN)

Consensus Ratings for Amgen (NASDAQ:AMGN) (?)
Ratings Breakdown: 1 Sell Rating(s), 9 Hold Rating(s), 12 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $184.26 (21.11% upside)

Analysts' Ratings History for Amgen (NASDAQ:AMGN)
Show:
DateFirmActionRatingPrice TargetActions
6/29/2016Goldman SachsReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Morgan StanleyReiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Sanford C. BernsteinInitiated CoverageMarket Perform$161.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/26/2016Leerink SwannReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016BMO Capital MarketsReiterated RatingOutperform$186.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Bank of AmericaReiterated RatingHold$182.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016RBC CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Robert W. BairdReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2016Citigroup Inc.Initiated CoverageNeutral$165.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016BTIG ResearchReiterated RatingSell$135.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016JPMorgan Chase & Co.Reiterated RatingNeutral$165.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016Jefferies GroupReiterated RatingBuy$187.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/8/2016ArgusLower Price TargetBuy$202.00 -> $185.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/29/2016Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016Wells FargoReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$202.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/22/2015NomuraReiterated RatingBuy$190.00 -> $191.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/31/2015Raymond JamesInitiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/17/2015Deutsche BankReiterated RatingBuy$195.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2015BarclaysBoost Price TargetEqual Weight$180.00 -> $185.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for Amgen (NASDAQ:AMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016        
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2015Q315$2.38$2.72$5.32 billion$5.72 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/21/2015Q115$2.10$2.48$4.91 billion$5.03 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/22/2014Q114$1.94$1.87$4.76 billion$4.52 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2013Q2 2013$1.74$1.89$4.49 billion$4.68 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.24 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.42 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/23/2012$1.47$1.67ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2012$1.54$1.83ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/26/2012$1.22$1.21ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/24/2011$1.29$1.40ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2011$1.29$1.37ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/20/2011$1.29$1.34ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/24/2011$1.11$1.17ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Amgen (NASDAQ:AMGN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$2.48$2.84$2.61
Q2 20164$2.58$2.76$2.68
Q3 20163$2.71$3.08$2.84
Q4 20163$2.68$3.01$2.83
Q1 20171$2.76$2.76$2.76
Q2 20171$2.83$2.83$2.83
Q3 20171$2.86$2.86$2.86
Q4 20171$2.90$2.90$2.90
(Data provided by Zacks Investment Research)
Dividend History for Amgen (NASDAQ:AMGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
3/2/2016quarterly$1.002.74%5/13/20165/17/20166/8/2016Tweet This Announcement  Share This Announcement on StockTwits
12/15/2015quarterly$1.002.43%2/11/20162/16/20163/8/2016Tweet This Announcement  Share This Announcement on StockTwits
10/14/2015quarterly$0.792.07%11/12/201511/16/201512/7/2015Tweet This Announcement  Share This Announcement on StockTwits
7/28/2015quarterly$0.791.84%8/13/20158/17/20159/8/2015Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015quarterly$0.791.98%5/12/20155/14/20156/5/2015Tweet This Announcement  Share This Announcement on StockTwits
12/17/2014quarterly$0.791.88%2/10/20152/12/20153/6/2015Tweet This Announcement  Share This Announcement on StockTwits
10/17/2014quarterly$0.611.77%11/10/201411/13/201412/5/2014Tweet This Announcement  Share This Announcement on StockTwits
7/25/2014quarterly$0.611.99%8/12/20148/14/20149/5/2014Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014quarterly$0.611.96%5/13/20145/15/20146/6/2014Tweet This Announcement  Share This Announcement on StockTwits
12/13/2013quarterly$0.612.18%2/11/20142/13/20143/7/2014Tweet This Announcement  Share This Announcement on StockTwits
10/16/2013quarterly$0.471.62%11/12/201311/14/201312/6/2013Tweet This Announcement  Share This Announcement on StockTwits
7/26/2013quarterly$0.471.72%8/14/20138/16/20139/6/2013Tweet This Announcement  Share This Announcement on StockTwits
3/6/2013quarterly$0.472.02%5/14/20135/16/20136/7/2013Tweet This Announcement  Share This Announcement on StockTwits
12/13/2012quarterly$0.472.11%2/11/20132/13/20133/7/2013Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)
Insider Trading History for Amgen (NASDAQ:AMGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Amgen (NASDAQ:AMGN)
DateHeadline
07/01/16 10:27 AMStiff Biosimilar Headwinds To Negatively Impact Amgen's Aging Drug Portfolio
07/01/16 10:07 AMWhat Are the Benefits of the Novartis-Xencor Alliance to Xencor? -
06/30/16 07:54 PMPfizer Inc. (NYSE:PFE) Bococizumab Edges Closer To Approval
06/30/16 07:54 PMAmgen (AMGN) Trading Near $147.71 Support Level
06/30/16 02:32 PMAnalyst Rating Trends to Observe: Merck & Company, Inc. (NYSE:MRK) , Amgen Inc. (NASDAQ:AMGN) - Street Updates
06/30/16 02:06 PMALXN 1210: Another of Alexion’s Important Pipeline Drugs -
06/30/16 10:18 AMParametric Portfolio Associates LLC Decreased Stake in Amgen INC (NASDAQ:AMGN) by $6.00 Million as Shares ... - Engelwood Daily
06/30/16 10:18 AMHC Stocks News Ring: Shire PLC (ADR) (NASDAQ:SHPG), Amgen, Inc. (NASDAQ:AMGN) - share market updates (press release)
06/29/16 01:24 PMBehind the Recent Fall in BioMarin’s Premium Valuation -
06/29/16 10:42 AMNoteworthy Analysts Suggestions: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) , Amgen Inc. (NASDAQ ... - Street Updates
06/29/16 10:42 AMAmgen, Incyte Well Positioned Following Brexit - Benzinga
06/28/16 02:43 PMIs it the Best Time to Buy Amgen Inc (NASDAQ:AMGN)? - Street Report
06/28/16 07:44 AMDubuque Bank & Trust Company Increased Amgen INC (NASDAQ:AMGN) by $3.47 Million as Shares Declined - Press Telegraph
06/28/16 07:44 AMShares in Decline this Year Amgen Inc. (NASDAQ:AMGN) - Press Telegraph
06/28/16 07:44 AMWhy Amgen Currently Represents A Compelling Investment Opportunity - Seeking Alpha
06/27/16 02:49 PMHC Stocks in Top Row: Novavax, Inc. (NASDAQ:NVAX), Amgen, Inc. (NASDAQ:AMGN) - share market updates (press release)
06/27/16 02:49 PMOakbrook Investments LLC Decreased Stake in Amgen INC (NASDAQ:AMGN) by $3.65 Million as Shares Declined - Press Telegraph
06/27/16 10:24 AMAmgen, Inc. (AMGN) Stock: Good Fundamentals, Good Yield, Good Opportunity - <p><a rel="nofollow" href="http://investorplace.com">InvestorPlace</a><a rel="nofollow" href="http://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>A combination of dividend, fundamental, technical and implied volatility analysis has uncovered a solid opportunity in AMGN.</p> <p>The post <a rel="nofollow" href="http://investorplace.com/2016/06/amgen-amgn-stock-opportunity/">Amgen, Inc. (AMGN) Stock: Good Fundamentals, Good Yield, Good Opportunity</a> appeared first on <a rel="nofollow" href="http://investorplace.com">InvestorPlace</a>.</p>
06/27/16 07:13 AMShort Sellers Run for Cover From Major Biotechs - 24/7 Wall St.
06/25/16 08:31 AMAnalysts: Amgen, Inc. (NASDAQ:AMGN)
06/24/16 07:41 PMAmgen Inc. (AMGN) Falls 3.82% for June 24 - Equities.com
06/24/16 09:11 AMAmgen Inc. (AMGN) is Trading Higher on Unusual Volume for June 22 - Equities.com
06/24/16 09:11 AMHC Stocks Impression: Amgen, Inc. (NASDAQ:AMGN), StemCells Inc (NASDAQ:STEM) - share market updates (press release)
06/24/16 08:56 AMBrexit means little for biotech stocks, analyst says -
06/24/16 01:20 AMTakeda Revises Collaboration Agreement with Amgen, Returning the Development and Commercialization Rights of Molecules / Products for Japan - [at noodls] - Osaka, Japan, June 24, 2016 - Takeda Pharmaceutical Company Limited (TSE: 4502) today announced revisions on an existing collaboration agreement, under which Takeda had rights to develop and commercialize ...
06/23/16 09:53 PMAmgen Inc. (AMGN) is Trading Higher on Unusual Volume for June 22
06/23/16 03:56 PMActive Runners: Marathon Oil Corporation (NYSE:MRO), Amgen, Inc. (NASDAQ:AMGN) - NYSE Journal (press release)
06/23/16 03:56 PMPrice Target Spotlight: Amgen Inc. (NASDAQ:AMGN) - News Oracle
06/23/16 03:56 PMHC Stocks to watch for: Amgen, Inc. (NASDAQ:AMGN), Sanofi SA (ADR) (NYSE:SNY) - share market updates (press release)
06/23/16 10:17 AMAmgen : Sponsors [email protected] Incubator For Life Science Startups
06/23/16 09:41 AMThe 3 Most Important Data Releases and FDA Decisions in the Second Half of 2016 -
06/23/16 09:36 AMWhy Biotechnology Goliath Amgen Is a Solid Long-Term Investment -
06/22/16 07:38 PMTop Gainers of the Day: Amgen Inc. (NASDAQ:AMGN) from Biotechnology - Twin County News
06/22/16 07:38 PMMarket Update: Amgen Inc (NASDAQ:AMGN) – Amgen Sponsors [email protected] Incubator For Life Science Startups - Jutia Group (press release) (blog)
06/22/16 05:09 PMAmgen Sponsors [email protected] Incubator For Life Science Startups - [at noodls] - SAN FRANCISCO, June 22, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a five-year, platinum sponsorship of the [email protected] life sciences incubator to accelerate the development of new therapies ...
06/22/16 11:22 AMMedicare 'Death Panel' Is On Ice; Biotech Stocks Heat Up -
06/22/16 07:14 AMHC Stocks Zone: Shire PLC (ADR) (NASDAQ:SHPG), Amgen, Inc. (NASDAQ:AMGN) - share market updates (press release)
06/21/16 03:24 PMNoteworthy Tuesday Option Activity: AMGN, GILD, OSIS - Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Amgen Inc (NASD: AMGN), where a total volume of 10,779 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 44.7% of AMGN's average daily trading volume over the past month, of 2.4 million shares. Especially high volume was seen for the $135 strike put option expiring August 19, 2016, with 922 contracts trading so far today, representing approximately 92,200 underlying shares of AMGN. Below is a chart showing AMGN's trailing twelve month trading history, with the $135 strike highlighted in orange:
06/21/16 02:24 PMAmgen Inc. (NASDAQ:AMGN) Current Analyst Ratings - Fiscal Standard
06/21/16 02:24 PMHC Stocks News Ring: UnitedHealth Group Inc (NYSE:UNH), Amgen, Inc. (NASDAQ:AMGN) - share market updates (press release)
06/21/16 12:22 PMWhy Biotech is Getting Crushed -
06/20/16 02:27 PMStock's Ratings to Focus: CVS Health Corporation (NYSE:CVS) , Amgen Inc. (NASDAQ:AMGN) - Street Updates
06/20/16 08:58 AMAmgen : Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen
06/20/16 06:17 AMAmgen Is Looking Vulnerable to a Deep Selloff -
06/19/16 07:13 AMAmgen Inc. (NASDAQ:AMGN) Analyst Price Targets For The Coming Week - Fiscal Standard
06/18/16 07:12 AMCompany Update: Amgen Inc (NASDAQ:AMGN) - Amgen Appoints Esteban Santos Executive Vice President, Operations - Jutia Group (press release) (blog)
06/17/16 03:39 PMBRIEF-Amgen names Esteban Santos executive VP, operations - * Amgen appoints Esteban Santos executive vice president, operations
06/17/16 02:26 PMEye Catching Stock: Amgen Inc. (NASDAQ:AMGN) - News Oracle
06/17/16 10:23 AMAmgen's Near-Term Catalyst Is Ph3 IVUS According To Goldman Sachs
06/17/16 10:23 AMAmgen Inc. (NASDAQ:AMGN) To Report June 2016 Results
About Amgen

Amgen logoAmgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Its products in Phase III programs include Aranesp for Myelodysplastic syndromes; ENBREL for Psoriatic arthritis and Rheumatoid arthritis remission; IMLYGIC for Metastatic melanoma, and Kyprolis for Multiple myeloma.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AMGN
  • CUSIP: 03116210
Key Metrics:
  • Previous Close: $152.15
  • 50 Day Moving Average: $153.02
  • 200 Day Moving Average: $153.03
  • P/E Ratio: 16.35
  • P/E Growth: 1.63
  • Market Cap: $116.09B
  • Current Quarter EPS Consensus Estimate: $11.17 EPS
Additional Links:
Amgen (NASDAQ:AMGN) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha